Biohaven Announces Submission of IND for BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist for the Treatment of Migraine
BHV-3500 is the first intranasal (IN) formulation of a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist to be advanced for human dosing in clinical trials
NEW HAVEN, Conn., Sept. 12, 2018 -- (Healthcare Sales & Marketing Network... Biopharmaceuticals, Neurology, FDA Biohaven Pharmaceutical, rimegepant, migraine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Brain | Clinical Trials | Genetics | Headache | Marketing | Migraine | Neurology | Pharmaceuticals